Stockhouse

LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edema

SEATTLE , May 7, 2021 /CNW/ -- LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular damage and diseases, today announced research ...
Business Wire

LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients

SEATTLE--(BUSINESS WIRE)--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced an update on the regulatory status of the ...
FierceBiotech

FDA clears its first treatment for dry AMD, with LumiThera's light-based Valeda system

Let there be green light: The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as being capable of improving a patient’s vision equal ...
Business Wire

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

SEATTLE--(BUSINESS WIRE)--LumiThera, Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular damage and disease, today announced a new Category III CPT code ...
Finanznachrichten

LumiThera Inc.: LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda Light Delivery ...

LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the initiation of the largest PBM trial ever conducted in patients ...
Healio

Vision improvements sustained with photobiomodulation at 24 months in dry AMD trial

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Pharmabiz

LumiThera presents benefits of photobiomodulation treatment using Valeda System in patients with early diabetic retinopathy with macular edema

LumiThera Inc, a commercialization-stage medical device company providing photobiomodulation therapy (PBM) for eye disorders and eye disease, announced that researchers led by the Dr Hakan Kaymak, ...
Medindia

LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edema

SEATTLE, May 7, 2021 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular damage and diseases, today announced research ...